Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA drug recalls in 2022

Every FDA drug recall initiated in 2022, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.

1,390 recalls, newest first.

Class I · High risk

Hcg 6

Non-sterility; bacterial contamination identified as Paenibacillus lautus.

Terminated Microbial contamination Revive Rx LLC dba Revive Rx Pharmacy D-0648-2022
Class I · High risk

RISE UP RED EDITION Capsules

Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared tadalafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.

Terminated Chemical / undeclared Positive Health D-0645-2022
Class I · High risk

Avaphinal Maximum Male Enhancement Sexual Pills

Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared sildenafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.

Terminated Chemical / undeclared Walmart Stores D-0725-2022
Class II · Moderate risk

Diazepam Oral Solution

Failed Impurities/Degradation Specifications: Out of specification results for related substances.

Terminated Impurity / degradation Lannett Company, Inc. NDC 0527-1768-36 D-0558-2022
Class I · High risk

RED MAMMOTH capsules

Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared sildenafil and tadalafil, ingredients found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.

Terminated Chemical / undeclared Celebrate Today D-0638-2022
Class I · High risk

The Red Pill

Marketed Without An Approved NDA/ANDA: Product was found to contain undeclared tadalafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.

Terminated Chemical / undeclared Your Favorite Shop D-0630-2022
Class I · High risk

MAC DADDY PURPLE Capsules

Marketed Without An Approved NDA/ANDA: product was found to contain undeclared tadalafil and/or sildenafil, ingredients found in FDA approved products for the treatment of male sexual enhancement, making these unapproved drugs.

Terminated Chemical / undeclared ABC Sales 1 Inc D-0563-2022
Class I · High risk

MAC DADDY RED Capsules

Marketed Without An Approved NDA/ANDA: product was found to contain undeclared tadalafil and/or sildenafil, ingredients found in FDA approved products for the treatment of male sexual enhancement, making these unapproved drugs.

Terminated Chemical / undeclared ABC Sales 1 Inc D-0562-2022
Class II · Moderate risk

Erythromycin Topical Gel USP

Failed Impurities/Degradation Specifications: Lot not meeting specification for Unknown Max Related Compounds.

Terminated Impurity / degradation Teligent Pharma, Inc. NDC 63739-053-66 D-0716-2022
Class II · Moderate risk

Chlorthalidone Tablets USP 25 mg

Foreign Matter identified as stainless steel microscopic wear particles mixed with punch lubricant oil and silicone particles from the dust cup

Terminated Particulate / foreign matter Sun Pharmaceutical Industries INC NDC 57664-648-88 D-0578-2022
Class II · Moderate risk

Methylphenidate Hydrochloride Chewable Tablets

Failed Tablet Specifications: Recall of this drug product was voluntarily initiated by the manufacturer due to a market complaint, which stated that a tablet in the sealed bottle was twice larger in size when compared to the remaining tablets. This complaint is second of its kind.

Ongoing Failed specification Rising Pharmaceuticals NDC 64980-221-01 D-0573-2022
Class II · Moderate risk

Prevantics

cGMP deviations: uncertainty of the adequacy of the validation of the test methods used to manufacture the products.

Terminated cGMP deviation Professional Disposables International, Inc. NDC 10819-4077-1 D-0572-2022
Class II · Moderate risk

Prevantics

cGMP deviations: uncertainty of the adequacy of the validation of the test methods used to manufacture the products.

Terminated cGMP deviation Professional Disposables International, Inc. NDC 10819-1080-1 D-0571-2022
Class II · Moderate risk

Prevantics

cGMP deviations: uncertainty of the adequacy of the validation of the test methods used to manufacture the products.

Terminated cGMP deviation Professional Disposables International, Inc. NDC 10819-4076-4 D-0570-2022
Class I · High risk

MegMan Performance Booster

Marketed Without An Approved NDA/ANDA: product was found to contain undeclared tadalafil, an ingredient found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.

Terminated Chemical / undeclared Junp Hydration LLC D-0557-2022

Recalls by year